| Wissenschaftl. Titel | A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15 |
| Erkrankung |
Haema:
AML:
Erstlinie
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (NIH) |
erstellt 20.02.2020 Data entry I CCP
geändert 19.12.2023 Data entry III CCP